Uterine serous carcinoma: Key advances and novel treatment approaches

Keyphrases

• Uterine Serous Carcinoma 100%
• Novel Treatments 100%
• Advance Treatment 100%
• Endometrial Cancer 50%
• Histology 16%
• Improved Outcomes 16%
• Phase II Study 16%
• Human Epidermal Growth Factor Receptor 2 (HER2) 16%
• Treatment Options 16%
• Overexpression 16%
• Poor Prognosis 16%
• Molecular Genetic Analysis 16%
• Conventional Chemotherapy 16%
• Black Women 16%
• Trastuzumab 16%
• Homologous Recombination 16%
• Mortality Rate 16%
• Pembrolizumab 16%
• Targeted Treatment 16%
• HER2-positive 16%
• TP53 mutation 16%
• Targeted Agents 16%
• Lenvatinib 16%
• Recent Advances 16%
• Recurrent Disease 16%
• Cancer Mortality 16%
• Incidence Rate 16%
• Somatic mutation 16%
• Targeted Therapeutics 16%
• Improved Survival 16%
• Advanced Disease 16%
• Advancing Age 16%
• Breast Cancer Family History 16%
• % Response 16%
• Plateaued 16%
• Clinical Risk Factors 16%
• Cancer Subtypes 16%
• Mutation Mutation 16%
• Tailored Treatment 16%
• Molecular Drivers 16%
• ERBB2 Amplification 16%
• PIK3CA mutation 16%
• FBXW7 mutation 16%
• Actionable Target 16%
• PPP2R1A 16%
• CCNE1 Amplification 16%
• Hereditary Breast Ovarian Cancer Syndrome 16%
• Working Diagnosis 16%
• Gynecologic Malignancies 16%
• HER2-targeted Therapy 16%

Medicine and Dentistry

• Uterine Serous Carcinoma 100%
• Uterine Cancer 50%
• Cancer 33%
• Diseases 33%
• Breast Cancer 16%
• Genetic Analysis 16%
• Targeted Therapy 16%
• Homologous Recombination 16%
• Recurrent Disease 16%
• Mortality Rate 16%
• Somatic Mutation 16%
• Lenvatinib 16%
• Hereditary Breast-Ovarian Cancer Syndrome 16%
• Tamoxifen 16%
• Trastuzumab 16%
• Pembrolizumab 16%
• Treatment Option 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinoma 100%
• Endometrium Cancer 50%
• Diseases 33%
• Chemotherapy 16%
• Tamoxifen 16%
• Syndrome 16%
• Ovary Cancer 16%
• Breast Cancer 16%
• Lenvatinib 16%
• Pembrolizumab 16%
• Recurrent Disease 16%
• Mortality Rate 16%
• Trastuzumab 16%